Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05630183 · ClinicalTrials.gov registry record · Phase 2

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Agenus.

Active
Registry status
Phase 2
Development phase
81
Enrollment target
20
Study locations

NCT05630183 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Agenus. The registered enrollment target is 81 participants, below the 180-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05630183, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Agenus.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
81 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

Conditions Studied

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • DRUG Botensilimab

Study Locations (20)

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • USC Norris Oncology - Newport Beach
  • UCLA Health - Santa Monica Cancer Care - Santa Monica

Florida

  • Florida Cancer Specialist South - Fort Myers
  • Cancer Care Centers of Brevard - Palm Bay
  • Florida Cancer Specialist North - St. Petersburg

New Jersey

  • John Theurer Cancer Center at Hackensack - Hackensack
  • Atlantic Health Systems, Morristown - Morristown
  • Overlook Medical Center - Summit

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Arizona

  • HonorHealth - Scottsdale

Delaware

  • Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center - Newark

Illinois

  • Illinois Cancer Specialists - Arlington Heights

Maryland

  • Maryland Oncology Hematology - Columbia

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2023-03-27
Est. Completion 2025-12-05
Phase Phase 2

Sponsor

Agenus

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05630183

The ClinicalTrials.gov registry entry for NCT05630183 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (55% lower). The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.

NCT05630183 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05630183 about?

NCT05630183 is a clinical study titled "A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer". The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participan...

What is the current status of trial NCT05630183?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2023-03-27. Estimated completion is 2025-12-05.

What conditions does trial NCT05630183 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT05630183?

The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Botensilimab (DRUG).

Who is sponsoring clinical trial NCT05630183?

This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05630183 being conducted?

This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.